This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ironwood Pharmaceuticals Inc (IRWD)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 76.44M 22.88M 150.25M 65.87M
Cost of Sales 12.17M 7.20M 965.00K 0.00
Gross Operating Profit 64.27M 15.68M 149.28M 65.87M
Selling, General, and Administrative Expenses 118.33M 165.30M 108.57M 45.92M
Research & Development 101.89M 102.38M 113.47M 86.09M
Operating Income before D & A (EBITDA) -155.95M -252.00M -72.76M -66.14M
Depreciation & Amortization 13.42M 12.98M 12.48M 10.00M
Interest Income 257.00K 192.00K 197.00K 456.00K
Other Income - Net 661.00K 0.00 0.00 900.00K
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) -168.45M -264.79M -85.05M -74.78M
Interest Expense 21.17M 21.00M 59.00K 63.00K
Pre-Tax Income -189.62M -285.80M -85.11M -74.85M
Income Taxes 0.00 0.00 0.00 3.00K
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations -189.62M -272.81M -72.62M -64.85M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations -189.62M -272.81M -72.62M -64.85M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income -189.62M -272.81M -72.62M -64.85M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-189.62M -272.81M -72.62M -64.85M
Preferred Dividends
Net Income Available To Common -189.62M -272.81M -72.62M -64.85M
Basic EPS from Continuing Ops. -1.39 -2.35 -0.68 -0.65
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations -1.39 -2.35 -0.68 -0.65
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total -1.39 -2.35 -0.68 -0.65
Basic Normalized Net Income/Share -1.39 -2.35 -0.68 -0.65
EPS fr Continuing Ops. -1.39 -2.35 -0.68 -0.65
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. -1.39 -2.35 -0.68 -0.65
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total -1.39 -2.35 -0.68 -0.65
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
-1.39 -2.35 -0.68 -0.65
Dividends Paid per Share 0.00 0.00 0.00 0.00
IRWD News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

IRWD Ironwood Pharmaceuticals Inc

Chart of IRWD

Analysts Ratings for IRWD

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 2 2 2
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET IRWD ANALYST REPORT

IRWD Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs